Merck Just Bet $10 Billion on a COPD Drug. Here's Why.

The Deal Terms, Decoded

Merck is paying $107 per American Depositary Share in an all-cash transaction structured as a UK scheme of arrangement (basically the British version of an acquisition agreement that requires court approval in England and Wales).

The premium? 23% above Verona's last closing price and 39% above the 60-day volume-weighted average. That's a solid premium, but not a desperation overpay. Net of Verona's cash on hand, the deal comes out to about $9.8 billion.

Merck plans to fund it with a combination of cash, commercial paper, and new debt. The company also noted that most of the purchase price will be capitalized as an intangible asset tied to Ohtuvayre, then amortized over time. Translation: the accounting hit will be spread out over years rather than taken all at once.

Wall Street's Verdict: Cautiously Bullish

The market liked it. Verona shares jumped roughly 20% on the news. More surprisingly, Merck stock rose too, which doesn't always happen when a big pharma announces a pricey acquisition.

Jefferies analyst Andrew Tsai projected peak annual Ohtuvayre sales of $3 billion to $4 billion by the 2030s. TD Cowen raised its price target on Verona to $107 (matching the offer exactly) and called it a fair price for a drug with "multibillion-dollar potential." BMO Capital Markets analyst Evan Seigerman acknowledged the strategic logic but flagged the real question: can Merck actually execute the transition smoothly as Keytruda fades?

That's the tension at the heart of this deal. The math works on paper. But paper doesn't sell drugs.

Merck's Bigger Chess Game

This isn't Merck's first diversification play. The company has been on a deliberate shopping spree over the past two years, buying assets across ophthalmology (EyeBio), autoimmune disease (the CN201 bispecific antibody from Curon), and even animal health. It also snapped up Harpoon Therapeutics for T-cell engagers.

The pattern is clear: Merck knows that relying on Keytruda alone is like building your entire fantasy football team around one quarterback. When that QB retires, you'd better have depth on the roster.

Verona Pharma gives Merck something it badly needed: a non-oncology commercial asset with near-term revenue and a plausible path to blockbuster status. Most of Merck's recent acquisitions have been early-stage bets or platform plays. Ohtuvayre is already generating sales.

The Competitive Landscape Isn't Empty

Ohtuvayre won't have the COPD market to itself. The standard of care still revolves around inhaler combinations: LAMA/LABA bronchodilators, LABA/ICS combos, and triple therapy for more severe patients. Roflumilast and dupilumab are also in the mix for specific subgroups.

Ohtuvayre's sweet spot is patients who remain symptomatic despite being on those existing therapies. It's an add-on, not a replacement. That's both its strength (it doesn't need to displace established drugs) and its limitation (it's not going to become first-line therapy overnight).

There's also a pricing wrinkle. Cost-effectiveness reviews have noted that Ohtuvayre's incremental benefit, while real, comes at a price that exceeds commonly used value thresholds. Payers may push back. If insurers drag their feet on coverage, uptake could be slower than the peak-sales projections assume.

So, Was It Worth $10 Billion?

The honest answer: it depends on execution.

If Ohtuvayre captures even a fraction of the undertreated COPD population and hits the $3 to $4 billion peak-sales target, this deal will look smart in hindsight. Merck gets a diversified revenue stream right when Keytruda headwinds intensify. The premium was reasonable, the financing is manageable, and the strategic rationale is sound.

But Merck needs to prove it can commercialize a respiratory drug at scale, navigate payer negotiations, and expand the ensifentrine franchise into new combinations and indications. That's a lot of plates to spin while simultaneously defending Keytruda through patent litigation and rolling out the FDA-approved subcutaneous formulation (Keytruda Qlex) to retain patients.

The Keytruda cliff is coming whether Merck is ready or not. With this deal, they're betting that lungs can help cushion the fall.